When Anaïs Wong was asked if she’d be interested in joining an Alameda-based group that organizes historical re-enactments of ...

Join the South Street Seaport Museum for a hybrid Sea Chanteys & Maritime Music event, blending in-person and online ...

The Givenchy dress Hepburn wore in the opening scene of Breakfast at Tiffany's is likely her most well-known and oft-emulated ...

Fusion physicists have always been haunted by a ghost in the machine known as the Greenwald limit. It’s a frustratingly empirical ceiling: try to cram too much plasma into your magnetic donut (tokamak ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced breast cancer who received elacestrant plus everolimus or abemaciclib had “clinically ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...

Performances in N.Y.C. Advertisement Supported by Critic’s Notebook This fall the offerings at American Ballet Theater, now in its 85th year, included a tepid premiere and touching debuts in Agnes de ...

Merck (NYSE:MRK) and Eisai (OTCPK:ESALF) Tuesday said that their Phase 3 LITESPARK-011 trial met a key goal, showing improved progression-free survival for patients with advanced kidney cancer treated ...

A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...